tiprankstipranks
Genmab A/S (GB:0MGB)
LSE:0MGB

Genmab A/S Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
9Ratings
6 Buy
2 Hold
1 Sell
Based on 9 analysts giving stock ratings to
Genmab
A/S
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0MGB Stock Price Prediction

Average Price Target

kr2,515.35
▲(17.59% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is kr2,515.35 with a high forecast of kr3,139.00 and a low forecast of kr402.15. The average price target represents a 17.59% change from the last price of kr2,139.00.
Highest Price Targetkr3,139Average Price Targetkr2,515Lowest Price Targetkr402.15
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Bryan Garnier & Co Ltd
kr2100.00
Hold
-1.82%
Downside
Upgraded
Genmab upgraded to Neutral from Sell at Bryan GarnierGenmab upgraded to Neutral from Sell at Bryan Garnier
Berenberg Bank
kr2200.00
Hold
2.85%
Upside
Upgraded
Genmab upgraded to Hold from Sell at BerenbergGenmab upgraded to Hold from Sell at Berenberg
Mizuho Securities
kr2754.00
Hold
28.75%
Upside
Reiterated
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK2,754 at Goldman SachsGoldman Sachs analyst Graig Suvannavejh lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,754.00 (from DKK2,990.00) while maintaining a Neutral rating.
Bank of America Securities
kr2846.00
Buy
33.05%
Upside
Reiterated
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK2,846 at BofA SecuritiesBofA Securities analyst Sachin Jain lowered the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK2,846.00 (from DKK3,030.00) while maintaining a Buy rating.
Bernstein
kr3200.00
Buy
49.60%
Upside
Reiterated
Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,200 at BernsteinBernstein analyst Wimal Kapadia raised the price target on Genmab A/S (GEN:DC) (NASDAQ: GMAB) to DKK3,200.00 (from DKK3,150.00) while maintaining a Outperform rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0MGB Stock Forecast FAQ

What is GB:0MGB’s average 12-month price target, according to analysts?
Based on analyst ratings, Genmab A/S’s 12-month average price target is kr2,515.35.
    What is GB:0MGB’s upside potential, based on the analysts’ average price target?
    Genmab A/S has 17.59% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GB:0MGB a Buy, Sell or Hold?
          Genmab A/S has a conensus rating of Moderate Buy which is based on 6 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Genmab A/S’s price target?
            The average price target for Genmab A/S is kr2,515.35. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is kr3,139.00 ,the lowest forecast is kr402.15. The average price target represents 17.59% Increase from the current price of kr2,139.
              What do analysts say about Genmab A/S?
              Genmab A/S’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis